NCIC CLINICAL TRIALS GROUP  
BRAIN  
DISEASE SITE COMMITTEE MEETING AGENDA  
OPEN SESSIONS

Venue: Carlyle Room  
Date: Saturday, May 2nd 2015 Time: 9:00 a.m. – 12:00 p.m.  
Chair: Dr. Warren Mason

9:00 am Welcome and Introductions

Completed Studies

9:00 am CE.5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study - molecular substudy submitted to ASCO 2015 W. Mason

9:05 am CE.5S: Impact of chemotherapy (temozolomide) versus radiotherapy treatment on work, social function, anxiety and depression throughout the continuum of care in patients with low grade glioma in Canada A. Leis & M. Parkinson

9:10 am IND. 204: A Phase II study of the Phosphatidylinositol-3-OH Kinase (PI3K) inhibitor PX-866 in recurrent glioblastoma - published in Neuro-Oncology M. Pitz

Trials Closed to Accrual

9:15 am CE.6: A Randomized Phase III Study of Temozolomide a Short- Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients J. Perry & N. Laperrier

Actively Accruing Trials

9:20 am CEC.1 (EORTC 26053_22054): Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial W. Mason & C. O'Callaghan

9:25 am CEC.3 (NCCTG N107C): A phase III trial of post-surgical stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease D. Roberge

Trials Pending Activation

9:30 am CEC.5 (ALLIANCE 221208): Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases C. Chung
9:45 am  **CEC.6 (NCCTG N0577):** Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma

W. Mason & C. O'Callaghan

10:00-10:15  Coffee Break

**New Trials for Discussion**

10:15 am  **IND.222:** A phase I/II trial of AZD2014 with temozolomide in patients with GBM at first progression  
C. Maurice and W. Mason

10:30 am  A randomized phase II trial of Toca511 with Toca FC for patients with newly diagnosed GBM receiving RT with (MGMT methylated) and without (MGMT unmethylated) Temozolomide  
J. Skillings

10:55 am  Triphase Pipeline for GBM  
M. Trikha

11:20 am  A Phase II Trial of SMO/AKT/FAK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations: ALLIANCE A071401  
W. Mason & C. O'Callaghan

11:30 am  A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation: ALLIANCE A071102  
W. Mason

**Miscellaneous**

11:40 am  Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project Status Report  
W. Mason

11:45  International Rare Cancer Initiative (ICRI) – Medulloblastoma Concept  
W. Mason

11:50 am  Report from NCIC CTG Leadership Retreat  
W. Mason & C. O'Callaghan

11:55 am  Report from IND Committee  
M. Pitz

12:00 pm  **Closing Remarks**